Editorial fellow Dr Ariel Wampler describes what few know about material and device regulation, and Dr Adriane Fugh-Berman explains why we should ask more questions about device representatives’ intraoperative roles during implantations.
Jeffrey Bedard joins Ethics Talk to discuss his article: "What Should Patients Be Told About Device Representatives’ Roles at the Point of Surgical Care?"
Madison L. Esposito and Michelle Kahn-John, PhD, RN
Most clinicians receive little training in integrating Native healing into allopathic practice, which undermines patients’ autonomy and cultural values.
AMA J Ethics. 2020;22(10):E837-844. doi:
10.1001/amajethics.2020.837.
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Graphic pathographies can illustrate how overreliance on statistics can obscure the clinical relevance of patients’ experiences of anxiety when they’re presented with prognoses.
AMA J Ethics. 2018;20(9):E897-901. doi:
10.1001/amajethics.2018.897.
Divya Yerramilli, MD, MBE, Alexandra Charrow, MD, MBE, and Arthur Caplan, PhD
Physicians should be aware of the powerful impact celebrities’ cancer narratives can have on patients’ experiences of their illnesses and treatment decisions. Partnering with celebrities is one strategy for delivering evidence-based health information and messaging to the public.
AMA J Ethics. 2018;20(11):E1075-1081. doi:
10.1001/amajethics.2018.1075.